CB 03 01

Drug Profile

CB 03 01

Alternative Names: Breezula; CB-03-01; Cortexolone 17alpha-propionate; Winlevi

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Cosmo Pharmaceuticals
  • Developer Cassiopea; Cosmo Pharmaceuticals; Intrepid Therapeutics
  • Class Esters; Pregnenediones; Propionates; Small molecules
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acne vulgaris
  • Phase II Alopecia

Most Recent Events

  • 01 May 2016 Intrepid Therapeutics completes a phase II trial in Alopecia in USA (NCT02279823)
  • 25 Mar 2016 Cassiopea plans a phase II trial for Acne vulgaris (In children) in USA and Poland (NCT02720627)
  • 01 Mar 2016 Cassiopea initiates enrolment in a phase-III extension trial for Acne vulgaris (In adolescents, In children, In adults) in USA (Topical) (NCT02682264)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top